Ultimovacs - Overall survival is the name of the NIPU PII game
Ultimovacs has announced that UV1 in combination with ipilimumab and nivolumab has shown clinically meaningful benefit in overall survival (reducing death risk by 27%), meeting a protocol-predefined threshold for statistical significance. Although overall survival (OS) is the secondary endpoint in the NIPU Phase II trial, OS is regarded as the gold standard in cancer treatment and is a critical consideration in malignant mesothelioma, an aggressive type of cancer with a high mortality rate and few therapeutic options in first-line treatment and no established standard of care in second-line treatment. This announcement follows the US FDA granting orphan drug designation (ODD) to UV1 for the treatment of mesothelioma and is a positive contrast from the June 2023 announcement (where a central independent review concluded the NIPU study did not meet the primary endpoint of progression-free survival). While we await the full study dataset to be presented by the lead investigator at ESMO 2023 (Saturday), these preliminary results are a positive indication of the vaccine’s efficacy. Shares reacted positively to the news and increased over 20% in early trading.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.